Printer Friendly

COMPANY INFORMATION
AEterna Zentaris Inc. 1405 boul du Parc-Technologique Québec, QC G1P 4P5 Tel: (418) 652-8525 Fax: (418) 652-0881 Contact Name Ginette Vallières Industry Biotechnology		Key Executives Jüergen Engel, CEO Dennis Turpin, CFO Discovers, develops and commercializes oncology and endocrine therapies to treat a variety of conditions, principally cancer. Product development pipeline includes Cetrorelix, Ozarelix and Perifosine.
FP ADVISOR COVERAGE AEterna Zentaris Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Investor Reports • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/AEZ Nasdaq/AEZS $0.88 $3.49 $0.72 n.a. n.a. n.a. 1.36 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 101,606 n.a. US$-0.94 Sept. 30/09 -16.19% -42.99% -27.21% $55,519
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08 12m Dec. 31/07 12m Dec. 31/06 US$000s US$000s US$000s Operating revenue 38,478 42,068 41,392 Net income (59,817) (32,296) 33,390 Total assets 108,342 123,363 223,491 US$ US$ US$ Earnings per share* (1.12) (0.61) 0.64 % % % Return on equity (108.69) (23.96) 5.06   * Common
TRAILING 12-MONTH VALUES Periods ended: Sept. 30/09 Sept. 30/08 US$000s US$000s Operating revenue 30,299 39,531 Net income (51,249) (58,960) US$ US$ Earnings per share (0.93) (1.11)

COMPANY NEWS

Results for 'AEterna Zentaris Inc.' from past 30 days: No hits. (Links are to articles.)